BCG Vaccines Sales Market Value to Grow $65 million by 2025, at CAGR of 4.2% | AMR

Pune, Maharashtra, India, December 16 2020 (Wiredrelease) Allied Analytics –:UPDATE AVAILABLE ON-DEMAND

The report on the global BCG vaccines sales market highlights that the market is expected to reach  $45 million in 2017, and is estimated to reach $65 million by 2025, growing at a CAGR of 4.2% from 2018 to 2025. The report offers the current market size and forecasts along with Porter’s Five Forces analysis to help market players, stakeholders, startups, and investors to determine the current scenario and take further steps for the future. Drivers and opportunities for highest revenue generating and fastest growing segments would help in tapping into specific segment to achieve growth. Moreover, regional analysis would assist in expansion strategies for the market players and startups.

BCG vaccine is a live attenuated vaccine used for the prevention of tuberculosis. The types of BCG drugs include immune BCG and therapy BCG. The BCG vaccines sales market growth has increased owing to gained prominence in the recent years due to high prevalence of tuberculosis worldwide and rise in number of drug-resistant tuberculosis cases. However, replacement for BCG vaccine is expected to restrain the market growth.

Download Free Report Sample @ https://www.alliedmarketresearch.com/request-sample/2604

The market report includes a detailed analysis of the Covid-19 impact on the BCG vaccines sales market. Over the course of 2020–2027, the market is expected to show significant growth. However, the recent Covid-19 outbreak is likely to affect some of the business operations. The report includes an analysis of how Covid-19 has and will affect the industry, studying reliable sources, interviews of experts, and annual reports of the major market players. The report includes major drivers, restraints, and opportunities within the BCG vaccines sales market.

Depending on drug type, the immune BCG segment is the highest revenue contributor and is also expected to exhibit the fastest growth rate of 4.9%. This is attributed to the wider use of BCG vaccine to acquire immunity against tuberculosis and absence of substitute to BCG vaccines currently.

For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/2604

Asia-Pacific was the highest revenue contributor in the global BCG vaccines sales market share, accounting for 70% of the total market in 2017. However, LAMEA is expected to grow at the highest rate, owing to the number of developing nations present in this region, rise in technological advancements in the vaccines procured, increased awareness, and higher disposable income.

Based on usage, the tuberculosis segment occupied the largest share of the market in 2017 and is expected to grow at the highest rate during the forecast period. Factors such as high prevalence of tuberculosis and large number of deaths due to tuberculosis globally significantly contribute toward the growth of this segment.

By end user, the pediatrics occupied the largest share in 2017, owing to increase in adoption of BCG vaccines due to its efficacy to prevent tuberculosis in pediatrics.

Access Full Report @ https://www.alliedmarketresearch.com/bcg-vaccine-sales-market

The Major Key Players Are:

AJ Vaccines, China National Pharmaceutical Group Corporation (Sinopharm), Greensignal Bio Pharma Limited, Intervax Ltd, Japan BCG Laboratory, Merck & Company Inc, Sanofi S.A., Serum Institute of India Pvt. Ltd., and Statens Serum Institute.

Key Findings of the BCG Vaccines Sales Market:

•    Europe occupied one-third share of the global BCG vaccines sales market in 2017.
•    The tuberculosis segment is anticipated to grow with the highest CAGR throughout the forecast period.
•    The pediatrics segment accounted for three-fourth share of the market in 2017.
•    Immune BCG is anticipated to grow at the highest rate during the analysis period.

Similar Reports:

Medical Sensors Market

Medical Bionic Implant/Artificial Organs Market

Gastrointestinal Therapeutics and Diagnostics Market

Vaccine Adjuvants Market

About Us:

Allied Market Research (AMR) is a full-service market research and business -consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com

This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.